

Ansell

For personal use only



Ansell FY26 Half Year Results

16 February 2026

Disclaimer and Non-IFRS Measures

The following presentation has been prepared by Ansell Limited (Ansell or the Company) for information purposes only. The information contained in this presentation is a summary only and does not purport to be complete. It should be read in conjunction with Ansell's other periodic and continuous disclosure announcements lodged with the Australian Securities Exchange, which are available at www.asx.com.au.

This presentation may contain forward-looking statements or statements of opinion. These statements can be identified by the use of forward-looking terminology such as 'may', 'will', 'should', 'expect', 'intend', 'anticipate', 'estimate', 'continue', 'assume', or 'forecast' or comparable terminology. These forward-looking statements are current only as at the date of this presentation. Although Ansell believes these forward-looking statements to be reasonable, they are not certain and involve unknown risks and assumptions (including many that may be outside of the control of Ansell). No representation or warranty (express or implied) is made regarding the accuracy, completeness or reliability of the forward-looking statements or opinion or the assumptions on which either are based. All such information is, by its nature, subject to significant uncertainties outside of the control of the Company. Subject to disclosure requirements, Ansell is under no obligation to update any forward-looking statements contained in this presentation.

Ansell, its related bodies corporate and any of its or their respective officers, directors, employees, agents or advisers (Ansell Parties), do not make any representation or warranty, express or implied, in relation to the accuracy, reliability or completeness of the information contained herein, and to the maximum extent permitted by law disclaim any responsibility and liability flowing from the use of this information by any party. To the maximum extent permitted by law, the Ansell Parties do not accept any liability to any person, organisation or entity for any loss or damage arising from the use of this presentation or its contents or otherwise arising in connection with it.

The information included in this presentation is not intended to be relied upon and is not investment or financial product advice. This presentation is not and should not be considered as an offer or recommendation with respect to the subscription for, purchase or sale of any security and neither this document, nor anything in it shall form the basis of any contract or commitment. Before making any investment decision, you should seek appropriate financial advice, which may take into account your particular investment needs, objectives and financial circumstances. Past performance is no guarantee of future performance. The statements in this presentation do not constitute an offer to sell, or solicitation of an offer to buy, any securities of Ansell.

NON-IFRS MEASURES

Ansell's financial results are reported under International Financial Reporting Standards (IFRS). This release includes certain non-IFRS measures including EBITDA, EBIT, GPADE, SG&A, EBIT and GPADE Margin, Adjusted EPS, Operating Cash Flow, Cash Conversion, Organic Constant Currency and Adjusted Sales Growth. These measures are presented to enable understanding of the underlying performance of the Company without the impact of non-trading items and foreign currency impacts. Non-IFRS measures have not been subject to audit or review.

AUTHORISED FOR RELEASE BY THE BOARD OF ANSELL LIMITED

Contents

1

Performance Overview

Neil Salmon
(Retiring Chief Executive Officer)

Double-digit earnings growth in subdued market conditions
On track to offset effects of higher US tariffs



2

Key Growth Drivers & Sustainability Update

Neil Salmon

Foundations in place for long term growth
Continued success with new products and enhancement of services offering



3

Financial Results

Brian Montgomery
(Chief Financial Officer)

Strong expansion in GPADE Margin driving higher EBIT, significant balance sheet flexibility



4

FY26 Outlook

Nathalie Ahlström
(Incoming Chief Executive Officer)

Previously announced on-market share buyback program to continue in FY26 H2
Maintaining guidance range for FY26 Adjusted EPS¹



5

Q&A

Neil Salmon
Nathalie Ahlström
Brian Montgomery



Performance Overview

Neil Salmon

For personal use only



Strong Delivery Against Key Performance Objectives



Our Previously Stated FY26 Goals

FY26 H1 Performance

Organic Constant Currency² sales growth

- ~ Subdued end market conditions
- ~ Organic CC² sales decline of 0.6%, improving to adjusted sales growth³ of 2.1% after excluding ~\$27m of previously disclosed sales in FY25 H1 that benefitted from temporary order pattern favourability

Pricing to offset higher US tariffs

- ✓ All price increases activated, tariff effects offset
- ✓ US business trading in line with expectations

Earnings supported by higher sales, improved manufacturing and supply chain productivity, and a step up in KBU synergies

- ✓ Strong expansion in GPADE Margin
- ✓ Increased KBU net cost synergies, on track to deliver ~\$12m in FY26
- ✓ APIP savings target fully achieved

Strong Cash Conversion⁵

- ✓ Cash Conversion⁵ of 112%, funding share buyback of \$47m and supporting reduction in Net Debt/EBITDA⁶ to 1.5x

Guidance range for Adjusted EPS⁴ of US137¢ to US149¢ (upgraded at October 2025 AGM)

- ✓ Guidance range maintained at US137¢ to US149¢

Summary Financials

(\$m) ¹	FY26 H1	% Δ	Organic CC % Δ ²
Sales	1,026.6	0.7%	(0.6%)
GPADE	358.9	7.4%	6.2%
Margin	35.0%	220bps	230bps
EBIT⁴	146.9	15.3%	15.4%
Margin	14.3%	180bps	210bps
Adjusted EPS⁴ (US¢)	66.3	19.0%	18.5%
Statutory EPS (US¢)	61.5	62.7%	
DPS (US¢)	26.60	19.8%	
Net Debt/EBITDA⁶	1.5x		

- Financials presented in US dollars millions on all slides of this presentation unless otherwise specified
- Organic CC (Constant Currency) compares FY26 H1 to FY25 H1 at Constant Currency and adjusts for the effects of acquisitions, divestments and business exits including the contribution from exited product groups that are no longer sold in FY26. Refer to slide 28 for further details
- Adjusted sales growth excludes previously disclosed sales in FY25 H1 that benefitted from temporary order pattern favourability from the Organic CC calculation, including ~\$17m in Healthcare from the fulfilment of surgical orders unable to be shipped in FY24 due to Red Sea disruptions, and ~\$10m in Industrial from customers increasing safety stocks of the Ringers® R840
- Before Significant Items
- Cash Conversion is defined as the percentage of net receipts from operations, excluding Significant Items, to EBITDA, and normalised for the timing of incentive and insurance payments
- Net Debt/EBITDA is based on LTM EBITDA, excluding Significant Items

On Track To Offset Effects Of Higher US Tariffs

Stated Pricing Objective



Pricing to offset higher US tariffs

- Total annualised cost ~\$80m



Pricing Implementation Status



All tariff-related price increases activated

- First wave of price increases completed in June 2025
- Activation of second wave from October 2025, all increases now announced



US Trading Performance



US business trading in line with expectations

Price increases offset combined effect of higher tariff costs and lower demand in tariff-affected verticals, in particular automotive manufacturing

- Negative demand effects also observed in other countries, particularly in Mexico



Continued Success With New Products In Industrial

Industrial Segment – Summary Financials

(\$m)	FY25 H1	FY26 H1	% Δ	Org CC ¹ % Δ
Sales	457.4	467.9	2.3%	1.2%
EBIT	70.9	83.9	18.3%	16.0%
EBIT/Sales	15.5%	17.9%		

FY26 H1 Sales Growth % Δ	Org CC ¹	Adjusted ²
Mechanical	2.3% →	5.9%
Chemical	(2.1%)	(2.1%)
Total Industrial	1.2% →	3.4%

1. Organic CC (Constant Currency) compares FY26 H1 to FY25 H1 at Constant Currency and adjusts for the effects of acquisitions, divestments and business exits including the contribution from exited product groups that are no longer sold in FY26. Refer to slide 28 for further details
2. Adjusted sales growth excludes previously disclosed sales in FY25 H1 that benefitted from temporary order pattern favourability from the Organic CC calculation, including ~\$17m in Healthcare from the fulfilment of surgical orders unable to be shipped in FY24 due to Red Sea disruptions, and ~\$10m in Industrial from customers increasing safety stocks of the Ringers® R840

Sales Performance

- Adjusted sales growth² of 3.4% in subdued market conditions, supported by tariff-related pricing in the US and higher sales in Mechanical
- Mechanical growth included continued success with new HyFlex® ultra-lightweight cut and Ringers® impact protection products
- Growth in protective clothing in Chemical, offset by lower gloves sales

EBIT Performance

- Organic CC¹ EBIT growth from higher sales, increased KBU synergies, lower freight costs as the usage of air freight dropped materially versus the prior period, and improved sourcing productivity



Improvement In Healthcare EBIT Margin

Healthcare Segment – Summary Financials

(\$m)	FY25 H1	FY26 H1	% Δ	Org CC ¹ % Δ
Sales	562.3	558.7	(0.6%)	(2.0%)
EBIT	64.4	72.5	12.6%	15.4%
EBIT/Sales	11.5%	13.0%		

FY26 H1 Sales Growth % Δ	Org CC ¹	Adjusted ²
Exam/SU	(2.9%)	(2.9%)
Surgical	(3.1%) →	7.2%
Cleanroom	2.8%	2.8%
Total Healthcare	(2.0%) →	1.1%

1. Organic CC (Constant Currency) compares FY26 H1 to FY25 H1 at Constant Currency and adjusts for the effects of acquisitions, divestments and business exits including the contribution from exited product groups that are no longer sold in FY26. Refer to slide 28 for further details
2. Adjusted sales growth excludes previously disclosed sales in FY25 H1 that benefitted from temporary order pattern favourability from the Organic CC calculation, including ~\$17m in Healthcare from the fulfilment of surgical orders unable to be shipped in FY24 due to Red Sea disruptions, and ~\$10m in Industrial from customers increasing safety stocks of the Ringers® R840

Sales Performance

- Adjusted sales growth² of 1.1%, with tariff-related pricing in the US and higher sales in Surgical partially offset by lower volumes in Exam/SU
- Exam/SU growth in more differentiated industrial single use products offset by lower sales of lower margin medical exam gloves
- Strong Surgical growth, driven by continued higher demand for synthetic products
- Continued growth in Cleanroom safety solutions

EBIT Performance

- Organic CC¹ EBIT growth from increased KBU synergies, lower freight costs as the usage of air freight dropped materially versus the prior period, and improved sourcing productivity



Key Growth Drivers & Sustainability Update

Neil Salmon

For personal use only



Accomplishments Of Last Four Years Better Position Ansell For Long Term Growth

Success With Digital Transformation, Improving Reliability & Agility

Enhanced digital capabilities foundational to accelerated sales growth, productivity gains and improved operating effectiveness

Unification of ERP systems in majority of manufacturing plants, paving way for commercial system upgrades and single company ERP solution

Leaner, More Productive & Customer Focused Organisation

APIP embedded **lower cost and more customer focused organisational structure**

Growth strategies better grounded in customer insights, supported by more focused global product teams

Strengthened Business Processes & Operating Effectiveness

Improved demand planning capabilities, supported by better analytics

Gains in service metrics, with improved customer experience evident in recognition from key channel partners


Consistent track record of key project delivery including accelerated KBU integration

Increased Presence In Higher Growth Markets & Enhanced Differentiation

KBU acquisition increased presence in attractive Scientific market, exited undifferentiated lower margin product lines

Growing momentum from new products addressing previously unmet customer safety needs

Strengthened service differentiation with capabilities most competitors can't match



Sales Supported By New Product Launches

Innovation Focus Areas

Comfort

Products that are **comfortable to wear** and **support hand & skin health**

Performance & Productivity

Longer lasting products supporting **job performance & worker productivity**

Protection

Enhanced protection, multi-hazard solutions **combining protection needs**

Sustainability

Environmentally-friendly materials and manufacturing processes

Key FY26 New Products

HyFlex® | 11-574 / 11-584 /
11-594 / 11-814 /
Precision comfort series with AEROFIT™ 11-844

Multi-purpose and cut protection gloves offering a second-skin fit for exceptional comfort and tactile control.



R570 / R580 / R590
Light duty impact-resistant gloves

Providing reliable impact and cut protection in a lightweight, flexible design that ensures comfort throughout the day, boosting productivity and reducing costs.



TouchNTuff® | 93-800
Nitrile disposable glove

The first disposable glove to be resistant to acetone for at least 15 minutes, providing superior protection against acetone exposure and enhanced resistance to other harsh chemicals for workers in a wide range of industrial environments.



AlphaTec® | 58-005 / 58-735
High-end chemical protective gloves, with cut protection / 58-835

Providing combined chemical and cut protection, comfort and durability for workers exposed to chemical hazards and handling sharp objects in a wide range of manufacturing industries.



AlphaTec® | Phantom
PFAS-free tactical suit for first response, hazmat and CBRN operations

Providing excellent protection against chemical and biological warfare agents as well as toxic industrial chemicals. Tested and approved in accordance with NFPA 1994 (1990) Class 1 & 2.



Further Enhancing Customer Intimacy Through Investment In Leading Service Solutions

Ansell **GUARDIAN**®

Data-driven, proprietary PPE assessment used by our safety experts to provide customers with **tailored product recommendations based on their specific needs**, including safety, compliance, productivity and sustainability


- ✓ Deploying AI to enhance report preparation speed and enrich dataset
- ✓ ~1,200 audits completed in FY26 H1, +30% versus FY25 H1



Ansell **GUARDIAN**™ Chemical

Digital suite of tools that **simplifies the chemical PPE selection process for an organisation**, based on its specific chemicals and applications

- ✓ Integrating AI safety data sheet reader, saving significant sales force time
- ✓ Expanding database to >130,000 chemicals
- ✓ >24,000 Chemical Guardian queries in FY26 H1, strong growth in North America & EMEA



RightCycle™

Product recycling service that reduces waste to landfill for non-hazardous laboratory, cleanroom and industrial PPE waste

- ✓ Broadening to include Industrial products
- ✓ European roll out in progress
- ✓ >260 tons of used PPE recycled in FY26 H1, +28% versus FY25 H1



Delivering Against Sustainability Objectives

Our 2040 Sustainability Action Plan Targets

FY26 H1 Progress

People



Reduce TRIFR

100% of direct suppliers¹ to meet Ansell's labour, health and safety standards by FY27

- ✓ Reduction in recordable accidents
- ✓ Increase in number of finished goods and raw material suppliers included in our Supplier Management Framework

Planet



Net zero emissions by FY45², including scope 3

Reduce water withdrawals by 35% by end of FY27³

Zero waste to landfill for all manufacturing plants

Improve environmental stewardship – fully compliant with EU Deforestation Regulation for natural rubber latex traceability

- ✓ Decrease in Scope 1 & 2 emissions
- ✓ Decrease in water withdrawals, on improved water usage practices and lower production
- ✓ Original scope facilities certified. Certification of new sites by 2027
- ✓ Ready for deployment in FY27 when the regulation becomes applicable

Products



Design 80% of new and updated products with reduced environmental impact by FY26⁴

- ✓ New products include HyFlex[®] sustainable high cut product family featuring >50% recycled content

1. In-scope suppliers based on Ansell's Supplier Management Framework
2. Less than 10% use of offsets
3. Versus FY20 baseline
4. Performance is measured according to Design for Sustainability (D4S) principles when compared with gloves of a similar make

Financial Results

Brian Montgomery

For personal use only



Double-Digit Earnings Growth

P&L Summary

(\$m)	FY25 H1	FY26 H1	% Δ	Org CC ¹ % Δ
Sales	1,019.7	1,026.6	0.7%	(0.6%)
Cost of Goods Sold	(620.9)	(605.3)	(2.5%)	(3.8%)
Distribution Costs	(64.7)	(62.4)	(3.6%)	(5.6%)
GPADE	334.1	358.9	7.4%	6.2%
SG&A	(206.7)	(212.0)	2.6%	0.4%
EBIT³	127.4	146.9	15.3%	15.4%
Significant Items ⁴	(30.3)	(7.3)	(75.9%)	
Net Interest	(19.9)	(20.2)	1.5%	0.5%
Taxes	(21.0)	(30.1)	43.3%	23.3%
Minority Interests	(1.2)	(0.5)	(58.3%)	(61.5%)
Statutory Profit Attributable	55.0	88.8	61.5%	
Adjusted Profit Attributable³	81.0	95.7	18.1%	17.7%
GPADE/Sales	32.8%	35.0%		
SG&A/Sales	20.3%	20.7%		
EBIT/Sales	12.5%	14.3%		
Adjusted Effective Tax Rate ³	23.5%	24.1%		
Statutory EPS (US¢)	37.8¢	61.5	62.7%	
Adjusted EPS³ (US¢)	55.7¢	66.3	19.0%	18.5%

Key Comments

- Organic CC¹ sales decline of 0.6%, improving to adjusted sales growth² of 2.1%
 - Adjusted sales growth² supported by tariff-related pricing in the US, partially offset by lower Exam/SU volumes in Healthcare
- GPADE margin increased 220bps
 - Margin accretion from lower freight costs and improved sourcing productivity
 - Combination of tariff-related pricing and higher tariff costs moderately dilutive to GPADE margin
- 0.4% Organic CC¹ SG&A growth, with higher employee costs partially offset by increased KBU cost synergies
- FX unfavourable to EBIT by \$1.6m, favourable translation effects offset by higher hedge contract losses versus FY25 H1
- Reduction in Significant Items⁴ versus FY25 H1 following completion of KBU transaction and integration in FY25
- Adjusted effective tax rate³ of 24.1%, in line with guidance

- Organic CC (Constant Currency) compares FY26 H1 to FY25 H1 at Constant Currency and adjusts for the effects of acquisitions, divestments and business exits including the contribution from exited product groups that are no longer sold in FY26. Refer to slide 28 for further details
- Adjusted sales growth excludes previously disclosed sales in FY25 H1 that benefitted from temporary order pattern favourability from the Organic CC calculation, including ~\$17m in Healthcare from the fulfilment of surgical orders unable to be shipped in FY24 due to Red Sea disruptions, and ~\$10m in Industrial from customers increasing safety stocks of the Ringers® R840
- Before Significant Items
- Significant Items in FY26 H1 includes \$5.4m one-off costs associated with the Accelerated Productivity Investment Program and \$1.9m other costs including legal costs associated with the shareholder class action. Significant Items in FY25 H1 includes \$6.4m one-off costs associated with the Accelerated Productivity Investment Program, \$10.0m one-off costs associated with the KBU transaction, \$12.9m one-off costs associated with the KBU integration, and \$1.0m other costs including legal costs associated with the shareholder class action

Healthy Balance Sheet

Balance Sheet Summary

(\$m)	Dec-24	Jun-25	Dec-25
Fixed Assets	362.1	377.2	404.0
Intangibles	1,638.2	1,655.5	1,655.1
Right of Use Assets	81.9	98.4	90.1
Other Assets/Liabilities	(56.0)	(136.4)	(99.1)
Working Capital¹	453.7	558.2	535.7
Inventories	525.4	584.7	577.2
Receivables ¹	162.2	212.4	191.3
Payables ¹	233.9	238.9	232.8
Capital Employed	2,479.9	2,552.9	2,585.8
Net Debt	556.8	570.2	583.0
Shareholders' Funds	1,923.1	1,982.7	2,002.8
ROCE % (Pre-Tax) ²	11.1%	12.8%	11.9%
ROE % (Post-Tax) ³	9.3%	9.5%	10.1%

1. Trade receivables and trade payables have had GST/VAT receivable and payable balances reclassified to other receivables and other payables
2. ROCE % calculated as LTM EBIT over average capital employed. LTM EBIT is adjusted to exclude Significant Items
3. ROE % calculated as LTM Profit Attributable over average shareholder funds. LTM Profit Attributable is adjusted to exclude Significant Items


Key Comments

- Strong balance sheet with Moody's Baa2 investment grade rating
- Improvement in working capital versus Jun-25
 - Reduction in inventory despite capitalisation of higher tariff costs in the US
 - Improvement in receivables largely due to collections seasonality, small reduction in payables due to lower purchases from outsourced finished goods suppliers
- Dec-25 ROCE includes full allocation of KBU capital employed, representing a ~70 basis point improvement versus Jun-25 on a like-for-like basis
 - Note KBU capital employed and equity funding only partially accounted for in Dec-24 and Jun-25 ROCE and ROE calculations, due to denominator averaging

Strong Cash Conversion¹



For personal use only



1. Cash Conversion is defined as the percentage of net receipts from operations, excluding Significant Items, to EBITDA, and normalised for the timing of incentive and insurance payments
2. Includes Significant Items
3. Operating Cash Flow is defined as net receipts from operations per the Consolidated Statement of Cash Flows adjusted for net payments for property, plant and equipment and intangible assets, repayments of lease liabilities, net interest paid, and tax paid

Key Comments

- Cash Conversion¹ of 112%, after normalising for the timing of incentive and insurance payments
- Working capital inflow on improved collections and lower inventory
- Other item bridging EBITDA to Net Receipts includes FY25 incentive payments made in Sep-25
- Net capex of \$28.2m included dipping line installations in our greenfield India Surgical facility
- Strong cash flow funded \$47.2m share buyback
- FY26 acquisitions outflow reflects acquisition of controlling interest in key manufacturing site in Sri Lanka. FY25 reflects acquisition of KBU

Significant Liquidity & Balance Sheet Capacity To Fund Growth Investments & Capital Management

Net Debt Summary

(\$m)	Dec-24	Jun-25	Dec-25
Interest-Bearing Debt	737.7	698.9	733.8
Cash at Bank and Short-Term Deposits	268.9	235.4	250.7
Net Interest-Bearing Debt (NIBD)	468.8	463.5	483.1
Lease Liabilities	88.0	106.7	99.9
Net Debt	556.8	570.2	583.0
Net Debt/EBITDA ¹	1.8x	1.6x	1.5x
Pro Forma Net Debt/EBITDA ²	1.6x	n/a	n/a


1. Net Debt/EBITDA is based on LTM EBITDA, excluding Significant Items

2. Pro Forma Net Debt/EBITDA for 31-Dec-24 includes KBU EBITDA for the six months from Jan-Jun 2024

Key Comments

- Reduction in Net Debt/EBITDA to 1.5x driven by strong earnings growth and working capital management
- Significant liquidity with \$719m of cash and undrawn bank facilities
- Debt profile has an average maturity tenor of 5.1 years
- 66% of debt facilities are at fixed interest rates, average interest rate on borrowings of 4.75%
- Substantial headroom within debt financial covenants which combined with strong liquidity and cash generation provides financial flexibility to fund a combination of internal investments, M&A and capital management

Drawn Debt Maturity Profile (\$m)



FY26 Outlook

Nathalie Ahlström

For personal use only



Initial Observations As Incoming CEO



Nathalie Ahlström has been appointed by the Board of Directors as Ansell's new Managing Director and CEO

"I'm honored to take on the role of CEO at Ansell. Across its 130-year history, Ansell has developed into a global leader in safety, innovating solutions that safeguard lives and enable businesses to thrive. That legacy of trust and impact is extraordinary, and it is a privilege to help shape its next chapter.

What drew me to Ansell is not only its leadership in protective solutions, but its unwavering commitment to a bold and meaningful vision: **Leading the world to a safer future.** This is more than a statement, it's a promise to protect lives, empower communities, and shape a future where safety enables progress everywhere.

Ansell's future is bright. Together, we will advance innovation, deliver sustainable growth, and make a positive impact on the world, while creating long-term value for our shareholders."



Key Priorities For Remainder Of FY26

Driving Sales Growth

- Build momentum from highly differentiated new product launches
- Commercialise AI-enabled services enhancements
- Continue to monitor trade policy developments and tariff-related demand effects

Improving Productivity


- Deliver KBU cost synergies
- Advance manufacturing automation investments
- Prepare for implementation of ERP system upgrades, starting in North America

Advancing Sustainability

- Sustain improvements in safety metrics
- Demonstrate effectiveness of reverse osmosis water recycling
- Broaden scope of Supplier Management Framework

Cash Flows & Capital Management

- Maintain strong cash conversion
- Continue with previously announced on-market share buyback program



Guidance Range For FY26 Adjusted EPS¹ Maintained At

US137¢ to US149¢

What We Expect To See

Guidance Assumptions

Sales

Stable end market conditions, increased sales

- Expecting organic constant currency² sales growth in FY26 H2
 - Market conditions expected to remain unchanged
 - Unmatched global presence and end-user focused sales approach provides growth opportunities in favoured verticals and geographies

Adjusted EPS¹

Earnings growth from higher sales, improved manufacturing and supply chain productivity, and a step up in KBU synergies

- On track to deliver incremental KBU net pre-tax cost synergies of ~\$7m versus FY25, bringing total FY26 net pre-tax cost synergies to ~\$12m
- FX headwind to EBIT of ~\$5m versus FY25, favourable currency movements offset by hedge book losses of >\$10m
- Net interest cost of ~\$43m
- Book tax rate of 23.5% to 24.5%

Cash Flow

Strong cash conversion and continued balanced approach to capital allocation

- One-off pre-tax costs (Significant Items, excluded from Adjusted EPS¹) of ~\$15m, primarily in relation to ERP system upgrades within the scope of APiP
- Capex of \$60m to \$70m
- Continuation of on-market share buyback program in FY26 H2

1. Before Significant Items

2. Organic CC (Constant Currency) compares FY26 H1 to FY25 H1 at Constant Currency and adjusts for the effects of acquisitions, divestments and business exits including the contribution from exited product groups that are no longer sold in FY26. Refer to slide 28 for further details

Q&A

Neil Salmon

Nathalie Ahlström

Brian Montgomery

For personal use only



Appendix

Ansell

For personal use only



APIP Update: Savings Goal Achieved, Preparing For Commercial ERP System Upgrades

Organisation

Simplify & Streamline Our Organisational Structure



- ✓ Changes completed in FY24
- ✓ Reorganised customer units benefiting from enhanced focus and contributing to improved sales momentum

Manufacturing

Improve Manufacturing Productivity



- ✓ Changes completed in FY25
- ✓ Gains in manufacturing productivity evident in GPADE margin expansion

IT

Accelerate Digitisation Strategy



- ✓ Multiple rounds of testing completed ahead of planned go live of upgraded ERP system in North America in coming months
- ✓ Other regions planned to cutover through FY27 and FY28

Summary Financials

APIP Savings

(annual versus FY23 baseline)

Annualised savings over the last 12 months total \$50m – total program savings goal achieved

APIP Cash Costs

FY24: \$44m

FY25: \$15m

FY26 H1: \$5m

Total Incurred: \$64m

Total Program Forecast: \$85-90m, including \$35m of IT costs

Sales & EBIT Impact Of FX Movements

	FX Impact (\$m)		Key Comments
	Sales	EBIT	
FY26 H1 vs FY25 H1			
FX Rate Movements	21.1	4.4	<ul style="list-style-type: none">Net improvement in Sales and EBIT, large positive movement in the EUR partially offset by adverse movements in the MYR and THB
FX Gain/(Loss) Variance – Hedge Contracts		(6.0)	<ul style="list-style-type: none">Net foreign exchange loss on hedge contracts in FY26 H1 was \$7.8m, the equivalent number in FY25 H1 was a loss of \$1.8m
Total	21.1	(1.6)	
FY26 H2 Forecast vs FY25 H2			
FX Rate Movements	~19	~2	<ul style="list-style-type: none">Based on our foreign exchange rate assumptions, we anticipate a positive net currency movement in FY26 H2, primarily driven by the EUR, partially offset by adverse movements in the MYR and THB
FX Gain/(Loss) Variance – Hedge Contracts		~(5)	<ul style="list-style-type: none">Favourable currency movement offset by expected losses on hedge contracts
Total	~19	~(3)	
FY26 Forecast vs FY25	~40	~(5)	


Input Costs Summary




FY26 H1 Input Cost Trends

- Decline in NBR and NRL costs versus FY25 H1, as well as synthetics and yarns
- Employee cost inflation persists in key manufacturing locations, including additional social compliance costs. Continued focus on productivity improvements to offset, including investment in automation technologies
- Energy costs stable
- Reduction in Exam/SU outsourced finished goods costs, on lower NBR costs
- Strengthening in key cost currencies including the MYR and THB

FY26 H1 COGS Components (COGS \$605.3m)



FY26 H1 Raw Material Mix



Organic Constant Currency

Constant Currency

- The presentation of constant currency information is designed to facilitate comparability of reported earnings by restating the prior period's results at the exchange rates applied in determining the results for the current period. This is achieved by analysing and estimating, where necessary, revenue and cost transactions by the underlying currencies of our controlled entities. These transactions are converted to US dollars at the average exchange rates applicable to the current period on a month-by-month basis (Currency Effect). In addition, the profit and loss impact of net foreign exchange gains/losses is excluded from the current and prior year's results (Net Exchange Loss).
- The principles of constant currency reporting and its implementation are subject to oversight by the Audit and Compliance Committee of the Board. It is considered as supplemental non-IFRS financial information.

Organic Constant Currency

- Organic constant currency compares the current period's performance to the prior period's results on a constant currency basis with organic adjustments, such as the effects of acquisitions, divestments, and business exits, including the contribution from exited product groups that are no longer sold in FY26.

Restated Prior Period (\$m)

	Industrial	Healthcare	Corporate	Group
Prior Period Sales				
Reported Sales	457.4	562.3	0.0	1,019.7
Less Exited Product Group	(6.3)	(2.0)	0.0	(8.3)
Remove Currency Effect	11.4	9.7	0.0	21.1
Organic Constant Currency Sales	462.5	570.0	0.0	1,032.5
Prior Period EBIT				
Reported EBIT	70.9	64.4	(7.9)	127.4
Less Exited Product Group	0.0	0.4	0.0	0.4
Remove Currency Effect	3.8	0.6	0.0	4.4
Remove Net Exchange Loss	0.8	1.0	0.0	1.8
Organic Constant Currency EBIT	75.5	66.4	(7.9)	134.0
Prior Period Profit Attributable				
Reported Profit Attributable				55.0
Remove Significant Items				26.0
Adjusted Profit Attributable				81.0
Less Exited Product Group				0.3
Remove Currency Effect				3.2
Remove Net Exchange Loss				1.5
Organic Constant Currency Profit Attributable				86.0

Segment History



(\$m)	FY16 ¹	FY17 ¹	FY18 ¹	FY19 ¹	FY20 ¹	FY21 ¹	FY22	FY23	FY24	FY25	1H20 ¹	1H21 ¹	1H22	1H23	1H24	1H25	1H26
Ansell																	
Sales	1,352.8	1,374.5	1,489.8	1,499.0	1,613.7	2,026.9	1,952.1	1,655.1	1,619.3	2,003.3	753.3	937.8	1,009.2	835.3	784.9	1,019.7	1,026.6
EBIT ^{2,3,4,5,6,7}	188.2	178.4	193.43	200.9	216.7	338.0	245.1	206.3	195.5	282.1	90.0	146.7	111.0	91.5	78.2	127.4	146.9
% Margin ^{3,4,5,6,7}	13.9%	13.0%	13.0%	13.4%	13.4%	16.7%	12.6%	12.5%	12.1%	14.1%	11.9%	15.6%	11.0%	11.0%	10.0%	12.5%	14.3%
Segments																	
Industrial	Sales	654.8	655.9	715.5	703.7	719.1	790.7	762.5	750.9	785.1	898.6	358.4	388.1	377.1	368.3	384.4	467.9
	EBIT ^{2,3,4,5,6,7}	82.8	79.8	86.9	98.7	92.4	112.4	107.0	103.9	129.3	155.5	44.4	57.9	56.3	42.8	58.2	70.9
	% Margin ^{3,4,5,6,7}	12.6%	12.2%	12.1%	14.0%	12.8%	14.2%	14.0%	13.8%	16.5%	17.3%	12.4%	14.9%	14.9%	11.6%	15.1%	17.9%
Healthcare	Sales	698.0	718.6	774.3	795.3	894.6	1,236.2	1,189.6	904.2	834.2	1,104.7	394.9	549.7	632.1	467.0	400.5	562.3
	EBIT ^{2,3,4,5,6,7}	116.5	110.1	120.1	115.3	141.8	248.8	150.7	113.4	81.1	141.9	54.6	100.4	63.7	55.9	27.3	64.4
	% Margin ^{3,4,5,6,7}	16.7%	15.3%	15.5%	14.5%	15.9%	20.1%	12.7%	12.5%	9.7%	12.8%	13.8%	18.3%	10.1%	12.0%	6.8%	11.5%
Corporate Costs		(11.1)	(11.5)	(13.6)	(13.1)	(17.5)	(23.2)	(12.6)	(11.0)	(14.9)	(15.3)	(9.0)	(11.6)	(9.0)	(7.2)	(7.3)	(7.9)

1. FY16-FY21 have been adjusted or restated retrospectively to apply the accounting policy change upon adoption of the April 2021 IFRIC Agenda Decision 'Configuration or Customisation Costs in a Cloud Computing Arrangement (IAS 38 Intangible Assets)'. Please note adjustments are included in Corporate Costs
2. FY16 Segment EBIT adjusted to include overhead costs previously allocated to Sexual Wellness and revised allocation methodology appropriate to new segments
3. EBIT and % Margin for FY18 and FY19 adjusted to exclude transformation costs and non-recurring items
4. EBIT and % Margin for FY22 and FY23 adjusted to exclude Russia exit costs
5. EBIT and % Margin for FY24 adjusted to exclude one-off costs associated with the Accelerated Productivity Investment Program, the KBU acquisition and integration, and legal costs associated with the shareholder class action
6. EBIT and % Margin for FY25 adjusted to exclude one-off costs associated with the Accelerated Productivity Investment Program, the KBU acquisition and integration, a non-cash charge against the value of retired brands, and legal costs associated with the shareholder class action
7. EBIT and % Margin for FY26 H1 adjusted to exclude one-off costs associated with the Accelerated Productivity Investment Program and legal costs associated with the shareholder class action

Ansell Fact Sheet



Key Figures

- Booked tax losses at 31 December 2025: \$23.9m
- Unbooked tax losses at 31 December 2025: \$17.3m (tax-effected)
- Unbooked capital losses at 31 December 2025: \$76.7m
- Interest rate on borrowings at 31 December 2025: 4.75% p.a.
- FY26 interim dividend: US26.60¢ per share (FY25 interim dividend US22.20¢ per share)
- Ordinary shares issued at 31 December 2025: 143.8m (145.9m at 31 December 2024)
- Weighted average no. of shares for FY26 H1 Adjusted EPS¹ calculation: 144.3m (145.4m for FY25 H1)

Key FY26 Assumptions

- Foreign exchange exposures by currency:
Revenue currencies: USD 55%, EUR 26%, CAD 4%, GBP 4%, CNY 3%, AUD 3%
Cost currencies: USD 63%, EUR 10%, MYR 10%, THB 6%, AUD 2%, CNY 2%
- Net interest cost of ~\$43m
- Tax rates, excluding one-off costs:
Book tax rate: 23.5% to 24.5%
Cash tax rate: 20% to 21%
- One-off pre-tax costs (Significant Items, excluded from Adjusted EPS¹) of ~\$15m, primarily in relation to ERP system upgrades within the scope of APIP
- Capex of \$60m to \$70m

1. Before Significant Items

Glossary



AI – Artificial Intelligence

APIP – Accelerated Productivity Investment Program

AUD – Australian Dollar

CAD – Canadian Dollar

Capex – Capital Expenditure

CC – Constant Currency

CNY – Chinese Yuan

COGS – Cost of Goods Sold

DPS – Dividend Per Share

EBIT¹ – Earnings Before Interest & Tax

EBITDA¹ – Earnings Before Interest, Tax, Depreciation and Amortisation

EPS – Earnings Per Share

ERP – Enterprise Resource Planning

EUR – Euro

FX – Foreign Exchange

FY – Financial Year (July – June)

GBP – Great British Pound

GPADE – Gross Profit After Distribution Expenses

H1 – First Half (July – December)

H2 – Second Half (January – June)

IFRIC – IFRS Interpretations Committee

KBU – Ansell's Kimtech™ and KleenGuard™ Business Unit (formerly Kimberly-Clark Corporation's Personal Protective Equipment Business)

LTM – Last 12 Months

MYR – Malaysian Ringgit

NBR – Nitrile Butadiene Rubber

NIBD – Net Interest-Bearing Debt

NRL – Natural Rubber Latex

ROCE – Return On Capital Employed

ROE – Return On Equity

Significant Items² – income or expense items that are unusual or infrequent, also known as non-recurring

SG&A – Selling, General and Administrative Expenses

SU – Single Use

THB – Thai Baht

TRIFR – Total Recordable Injury Frequency Rate

USD – United States Dollar

1. EBITDA and EBIT exclude Significant Items

2. Includes one-off costs associated with the Accelerated Productivity Investment Program and legal costs associated with the shareholder class action in FY26 H1. Includes one-off costs associated with the Accelerated Productivity Investment Program and the KBU transaction and integration, and legal costs associated with the shareholder class action in FY25 H1



Lead the world to a safer future.

www.ansell.com

For personal use only